Recent research has explored Hepatocyte Growth Factor as a potential target for managing Myasthenia Gravis. This involves studying its role in experimental models of the disease, aiming to identify new pathways for intervention.
The investigation into Hepatocyte Growth Factor reflects ongoing efforts to develop more effective treatments. By examining its role in experimental autoimmune myasthenia gravis models, researchers seek to improve symptom management and quality of life for patients, as noted in studies like those by Fan et al. (2025).
Clinical Trials
This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks:
More Info 
Add to Calendar